Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer

Status Completed

Clinical Trial Summary

The purpose of this study is to assess the safety and tolerability of rovalpituzumab tesirine (SC16LD6.5) at different dose levels in patients with small cell lung cancer whose cancer has progressed or recurred following standard chemotherapy. Once a safe and tolerable dose is determined, the anti-cancer activity of SC16LD6.5 will be assessed by measuring the extent of tumor shrinkage. SC16LD6.5 is an antibody-drug conjugate (ADC). The antibody (SC16) targets a protein that appears to be expressed on the surface of most small cell lung cancers that have been assessed using an immunohistochemical assay. The drug, D6.5, is a very potent form of chemotherapy, specifically a DNA-damaging agent, that is cell cycle independent. ADC's theoretically provide more precise delivery of chemotherapy to cancer cells, possibly improving effectiveness relative to toxicities.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01901653
Study type	Interventional
Source	Stemcentrx
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	July 2013
Completion date	November 28, 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01935336` - Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers	Phase 2
Completed	`NCT01931787` - CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer	Phase 1
Terminated	`NCT01217411` - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer	Phase 1
Terminated	`NCT04610658` - Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC	Phase 1
Completed	`NCT00773955` - R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer	Phase 2
Completed	`NCT00528645` - AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer	Phase 2
Completed	`NCT00028535` - Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors	Phase 1
Recruiting	`NCT03732846` - Anlotinib in Treatment of Recurrent Small Cell Lung Cancer	Phase 2
Active, not recruiting	`NCT00828139` - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer	Phase 2
Completed	`NCT00086827` - Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer	Phase 2
Completed	`NCT00052949` - Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer	Phase 2
Withdrawn	`NCT01325753` - Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body	N/A
Not yet recruiting	`NCT05162196` - The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer	Phase 2
Completed	`NCT01155258` - Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors	Phase 1
Terminated	`NCT00088933` - Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer	Phase 1
Completed	`NCT00020202` - FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer	Phase 2
Completed	`NCT00182689` - Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer	Phase 2
Completed	`NCT01457469` - Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer	Phase 1
Completed	`NCT00098956` - 7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer	Phase 2
Terminated	`NCT01803269` - Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer	Phase 2